Navigation Links
Hologic, Inc. to Host Investor Reception at the RSNA Trade Show
Date:11/20/2008

BEDFORD, Mass., Nov. 20 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company will host a meeting for members of the investment community who will be attending the RSNA (Radiological Society of North America) trade show in Chicago.

This meeting will be held on Tuesday, December 2, 2008, at McCormick Place from 8:00 - 10:00 AM (Central Time) and will include a presentation by members of Hologic's management team.

Interested participants may listen to the call (listen mode only) by dialing 800-260-8140 or 617-614-3672, password: 38598533 at 7:50 AM (Central Time) and referencing the Hologic Investor Meeting. This call is expected to last approximately thirty minutes. For those unable to participate in the live broadcast, a replay will be available one hour after the call ends through January 6, 2009 at 888-286-8010 or 617-801-6888 (pass code 92177800).

The Company will also provide a live webcast of the call. Interested participants may access the webcast at the Company's website at www.hologic.com. A replay of the call will be archived on the Company's website.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including reagents for a variety of DNA and RNA analysis applications.

    Contact: Deborah Gordon                     Frances Doria
             Vice President, Investor Relations Director, Investor Relations
             Hologic, Inc.                      Hologic, Inc.
             (781) 999-7716                     (781) 999-7377

'/>"/>
SOURCE Hologic, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
2. Hologic, Inc. to Release Second Quarter Fiscal 2008 Operating Results Thursday, May 1st Before Market Opens
3. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
4. Varian, Inc. CEO to Speak at the Nasdaq OMX 22nd Investor Program
5. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Pharmasset to Present at Two Upcoming Investor Conferences
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Deutsche Bank Conference
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Novavax Announces Release Date of 2008 Third Quarter Financial Results and Investor Conference Call
11. VIA Pharmaceuticals Announces Upcoming Investor Conference Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... today announces publication of a United States multicenter, prospective clinical study that ... disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial and ...
(Date:10/11/2017)... ... October 11, 2017 , ... The ... endogenous context, enabling overexpression experiments and avoiding the use of exogenous expression plasmids. ... is transformative for performing systematic gain-of-function studies. , This complement to loss-of-function ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , ... of Cancer Research, London (ICR) and ... with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple ... as MUK nine . The University of ... is partly funded by Myeloma UK, and ICR will perform ...
(Date:10/10/2017)... Los Angeles, CA (PRWEB) , ... ... ... Pharmaceuticals, Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) ... all uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed ...
Breaking Biology Technology:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):